Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):202–210. doi: 10.1097/QAI.0000000000002122

Figure 1. Study design of statin use association with eGFR, proteinuria, and urine biomarkers in HIV-infected men in MACS.

Figure 1.

Cumulative statin exposure captures duration of statin use prior to the baseline visit between 2009–2011. Urine biomarkers and eGFR were first measured at the baseline visit, and eGFR measures were repeated approximately every six months thereafter. Time-updated statin use captures statin exposure reported at each follow-up visit.